Citigroup Inc Annovis Bio, Inc. Transaction History

Citigroup Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$5.55 - $19.62 $62,143 - $219,685	11,197 New	11,197 $209,000
Q3 2022 Nov 10, 2022	BUY	$10.26 - $21.81 $10 - $21	1 Added 20.0%	6 $0
Q2 2022 Aug 10, 2022	SELL	$8.61 - $13.87 $602 - $970	-70 Reduced 93.33%	5 $0
Q1 2022 May 12, 2022	BUY	$11.84 - $19.78 $828 - $1,384	70 Added 1400.0%	75 $1,000
Q4 2021 Feb 10, 2022	BUY	$17.58 - $37.67 $87 - $188	5 New	5 $0

1.2M

779K

1.77M

Ticker ANVS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 8,163,920
Market Cap $45.4M
Description
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease ...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.